National survey on the susceptibility of Bacteroides fragilis group:: Report and analysis of trends for 1997-2000

被引:59
作者
Snydman, DR
Jacobus, NV
McDermott, LA
Ruthazer, R
Goldstein, EJC
Finegold, SM
Harrell, LJ
Hecht, DW
Jenkins, SG
Pierson, C
Venezia, R
Rihs, J
Gorbach, SL
机构
[1] Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Div Geog Med & Infect Dis, Boston, MA 02111 USA
[2] Tufts Univ, Sch Med, New England Med Ctr, Dept Community Hlth, Boston, MA 02111 USA
[3] Tufts Univ, Sch Med, New England Med Ctr, Dept Clin Res, Boston, MA 02111 USA
[4] RM Alden Res Lab, Santa Monica, CA USA
[5] Wadsworth VA Hosp, Los Angeles, CA USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Carolinas Med Ctr, Charlotte, NC 28203 USA
[8] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[9] Mt Sinai Med Ctr, New York, NY 10029 USA
[10] Albany Med Ctr, Albany, NY USA
[11] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[12] Vet Adm Med Ctr, Pittsburgh, PA USA
关键词
D O I
10.1086/341934
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The results of a multicenter US survey using the National Committee for Clinical Laboratory Standards currently recommended methodology for measuring in vitro susceptibility of 2673 isolates of Bacteroides fragilis group species were compared from 1997 to 2000. The test panel consisted of 14 antibiotics: 3 carbapenems, 3 beta-lactam-beta-lactamase inhibitors, 3 cephamycins, 2 fluoroquinolones, clindamycin, chloramphenicol, and metronidazole. Declines in the geometric mean minimum inhibitory concentrations were seen with imipenem, meropenem, ampicillin-sulbactam, and the cephamycins. Increased geometric means were observed with the fluoroquinolones and were usually accompanied by an increase in resistance rates. Bacteroides distasonis shows the highest resistance rates among beta-lactam antibiotics, whereas Bacteroides vulgatus shows the highest resistance levels among fluoroquinolones. B. fragilis shows the lowest resistance rates for all antibiotics. All strains were susceptible to chloramphenicol and metronidazole concentrations <8 μg/mL. The data underscore the need for species identification and continued surveillance to monitor resistance patterns.
引用
收藏
页码:S126 / S134
页数:9
相关论文
共 13 条
[1]   Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species [J].
Aldridge, KE ;
Ashcraft, D ;
Cambre, K ;
Pierson, CL ;
Jenkins, SG ;
Rosenblatt, JE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1238-1243
[2]   Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group:: Comparison with the activities of 14 other agents [J].
Betriu, C ;
Gómez, M ;
Palau, ML ;
Sánchez, A ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2320-2322
[3]   In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains [J].
Betriu, C ;
Sánchez, A ;
Palau, ML ;
Gómez, M ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2372-2374
[4]   Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections [J].
Goldstein, EJC ;
Citron, DM ;
Merriam, CV ;
Warren, Y ;
Tyrrell, KL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2389-2394
[5]  
Holdeman LV., 1977, Anaerobic laboratory manual, V4
[6]  
National Committee for Clinical Laboratory Standard, 1997, M11A4 NCCLS
[7]   Antimicrobial resistance and clinical outcome of bacteroides bacteremia: Findings of a multicenter prospective observational trial [J].
Nguyen, MH ;
Yu, VL ;
Morris, AJ ;
McDermott, L ;
Wagener, MW ;
Harrell, L ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) :870-876
[8]   WOUND AND INTRAABDOMINAL INFECTIONS - MICROBIOLOGICAL CONSIDERATIONS AND APPROACHES TO TREATMENT [J].
NICHOLS, RL ;
SMITH, JW .
CLINICAL INFECTIOUS DISEASES, 1993, 16 :S266-S272
[9]   CLINICAL RELEVANCE OF SUSCEPTIBILITY TESTING OF ANAEROBIC-BACTERIA [J].
ROSENBLATT, JE ;
BROOK, I .
CLINICAL INFECTIOUS DISEASES, 1993, 16 :S446-S448
[10]   Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996 [J].
Snydman, DR ;
Jacobus, NV ;
McDermott, LA ;
Supran, S ;
Cuchural, GJ ;
Finegold, S ;
Harrell, L ;
Hecht, DW ;
Iannini, P ;
Jenkins, S ;
Pierson, C ;
Rihs, J ;
Gorbach, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2417-2422